Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAA617 versus observation in PSMA-positive oligometastatic recurrent prostate cancer
jRCT2031230608Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing AAA617 with Observation (2 arms). Primary endpoint: Metastasis-free survival. Started May 2024; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031230608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230608.